… Lg ofantibodyjmL or a total of r- I mg) and the therapeutic dose (0.6 g) ofcapsular …
Schneerson R. Polysaccharide-protein conjugates: a new generation ofvaccines. J Infect …

Contributions to science and to the practice of medicine are built on the shoulders of our
predecessors. For us, the shoulders of Dr. Maxwell Finland were singularly broad and strong: In …

Immunoprophylaxis for bacterial enteric diseases is hindered because the protective
immune mechanism(s) against nontyphoidal salmonellae or shigellae in humans are not …

… in the following experiments, only an occasional animal responded to injection of purified
HIB Ps (R. … R Hilleman. 1978. Vaccination and revaccination with polyvalent pneumococcal …

Background In patients with decreased resistance to infection, Staphylococcus aureus is a
major cause of bacteremia and its complications. The capsular polysaccharides are essential …

We conducted a pilot study followed by a large clinical trial in Nepal of the use of the capsular
polysaccharide of Salmonella typhi (Vi) as a vaccine to prevent typhoid fever. In the pilot …

Background Typhoid fever is common in developing countries. The licensed typhoid vaccines
confer only about 70 percent immunity, do not protect young children, and are not used for …

… trial was to assess the efficacy of a conjugate vaccine composed of Shigella sonnei O-specific
polysaccharide bound to Pseudomonas aeruginosa recombinant exoprotein A (S sonnei-r …

The protective efficacy against typhoid fever of a single intramuscular injection of 25 μg of the
Vi capsular polysaccharide (CPS) was assessed in a randomised double-blind controlled …

The relationship of capsular types of Staphylococcus aureus to type of infection, carrier state,
and phage type was studied in a collection of 477 isolates from 380 infection sites. …